Chronic CaMKII inhibition blunts the cardiac contractile response to exercise training by Kaurstad, Guri et al.
ORIGINAL ARTICLE
Chronic CaMKII inhibition blunts the cardiac contractile
response to exercise training
Guri Kaurstad • Marcia N. Alves • Ole J. Kemi •
Natale Rolim • Morten A. Høydal • Helene Wisløff •
Tomas O. Stølen • Ulrik Wisløff
Received: 23 November 2010 / Accepted: 30 April 2011 / Published online: 26 May 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Activation of the multifunctional Ca2?/cal-
modulin-dependent protein kinase II (CaMKII) plays a
critical role modulating cardiac function in both health and
disease. Here, we determined the effect of chronic CaMKII
inhibition during an exercise training program in healthy
mice. CaMKII was inhibited by KN-93 injections. Mice
were randomized to the following groups: sham sedentary,
sham exercise, KN-93 sedentary, and KN-93 exercise.
Cardiorespiratory function was evaluated by ergospirome-
try during treadmill running, echocardiography, and car-
diomyocyte fractional shortening and calcium handling.
The results revealed that KN-93 alone had no effect on
exercise capacity or fractional shortening. In sham animals,
exercise training increased maximal oxygen uptake by 8%
(p \ 0.05) compared to a 22% (p \ 0.05) increase after
exercise in KN-93 treated mice (group difference
p \ 0.01). In contrast, in vivo fractional shortening eval-
uated by echocardiography improved after exercise in
sham animals only: from 25 to 32% (p \ 0.02). In inactive
mice, KN-93 reduced rates of diastolic cardiomyocyte re-
lengthening (by 25%, p \ 0.05) as well as Ca2? transient
decay (by 16%, p \ 0.05), whereas no such effect was
observed after exercise training. KN-93 blunted exercise
training response on cardiomyocyte fractional shortening
(63% sham vs. 18% KN-93; p \ 0.01 and p \ 0.05,
respectively). These effects could not be solely explained
by the Ca2? transient amplitude, as KN-93 reduced it by
20% (p \ 0.05) and response to exercise training was equal
(64% sham and 47% KN-93; both p \ 0.01). We con-
cluded that chronic CaMKII inhibition increased time to
50% re-lengthening which were recovered by exercise
training, but paradoxically led to a greater increase in
maximal oxygen uptake compared to sham mice. Thus, the
effect of chronic CaMKII inhibition is multifaceted and of
a complex nature.
Keywords Aerobic interval training  KN-93  Exercise
training and cardiac function  CaMKII inhibition in
healthy mice
Introduction
The ubiquitous and multifunctional Ca2?/calmodulin-
dependent protein kinase II (CaMKII) regulates a number
of intracellular processes related to cellular contractility
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and nuclear gene expression, thereby controlling the pump
function and growth of the heart. Some of the specific
targets include the L-type Ca2? channel, the sarcoplasmic
reticulum (SR) Ca2? release channel (ryanodine receptor 2,
RyR2), phospholamban (PLB), Na? and K? channels
making CaMKII a prominent regulator of excitation–con-
traction coupling (Couchonnal and Anderson 2008; Hash-
ambhoy et al. 2010; Maier et al. 2007; Maier and Bers
2002). Furthermore, CaMKII can regulate nuclear gene
expression on class II histone deacetylase (HDAC), which
increases myocyte-enhanced factor 2 (Mef2)-regulated
transcription (Erickson and Anderson 2008; Maier and
Bers 2002, 2007; Maier et al. 2007; Sag et al. 2009).
However, the functional consequences of CaMKII activa-
tion are still unclear, since heart failure is associated with
increased CaMKII (Anderson 2005; Anderson et al. 1998;
Couchonnal and Anderson 2008; Khoo et al. 2006; Vila-
Petroff et al. 2007; Zhang et al. 2005); in fact, CaMKII
may constitute a molecular switch between cardiac
hypertrophy and failure (Zhang et al. 2005), and CaMKII
activation may also precede arrhythmic events and con-
tractile dysfunction, mainly because of its effect on the
RyR2 (Anderson 2005; Ling et al. 2009; van Oort et al.
2010). On the other hand, improved contractile function
after aerobic interval exercise training also associates with
activated CaMKII, but in this scenario, the main effect is
on the SR Ca2? uptake due to phosphorylation of PLB.
Interestingly, in mice with type-2 diabetes with chronically
increased cardiac CaMKII and reduced cardiomyocyte
contractile function and Ca2? handling, aerobic interval
exercise training resulted in reduced levels of CaMKII and
improved cardiomyocyte contractile function and Ca2?
handling (Stolen et al. 2009). Recent studies have shown
that CaMKII negatively regulates calcineurin activity
(Khoo et al. 2006; MacDonnell et al. 2009), which in turn
regulates mitochondrial respiration, and further compli-
cates the role of CaMKII (Jiang et al. 2010; Wang et al.
2011).
The exact role of CaMKII activation in the heart
remains unclear, as it associates with dysfunction, failure,
and propensity for arrhythmias, but also with increased
function under different circumstances such as exercise
training. Based on the potential clinical value of chronic
CaMKII inhibition (Khoo et al. 2006; Sag et al. 2009;
Zhang et al. 2005) and the beneficial effect of exercise
training on delaying cardiac dysfunction and correcting
function after onset of heart disease (Stolen et al. 2009;
Wisloff et al. 2002, 2007; Adams et al. 2005; Erbs et al.
2010; Mezzani et al. 2008; Hambrecht et al. 2000;
Anderson et al. 1998; Kemi et al. 2007; Zhang et al. 2005)
two scenarios that may mutually oppose each other,
determining the effect of chronic CaMKII inhibition on the
response to exercise training would be of considerable
interest. Therefore, we aimed to study the effect of chronic
CaMKII inhibition during the course of an exercise training
program in healthy mice. We hypothesized that chronic
CaMKII inhibition would abolish the normal exercise
training response in the hearts.
Materials and methods
Mice and CaMKII inhibition
Eighteen female C57 BL/6J mice (Møllegaard Breeding
Center, Lille Skensved, Denmark) 18–20 g, 8 weeks of age
at inclusion were randomized into four groups: (1) sham
control sedentary, (2) sham control exercise training, (3)
KN-93 sedentary, and (4) KN-93 exercise training. KN-93
(2-[N-(2-hydroxyethyl)-N-(4 methoxybenzenesulfonyl)]
amino-N-(4-chlorocinnamyl)-N-methylbenzylamine; Alexis-
Biochemical, Enzo Life Science, PA, USA) diluted in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO,
USA, 2 mg KN-93/1 mL DMSO, 10 lmol/kg (Zhang et al.
2005)) was intraperitoneally injected daily after the exer-
cise training session (for those that exercise trained),
throughout the experimental period. In a previous study,
Zhang et al. (2005) observed dose-dependent CaMKII
inhibition by KN-93, in which daily injections of 10 lmol/
kg KN-93 produced similar effect on left ventricular con-
traction measurements as the genetically CaMKII-inhibited
AC3:I mice (Zhang et al. 2005; Khoo et al. 2006). Sham
control mice received similar amounts of DMSO daily. The
Norwegian council for Animal Research approved the
study, which was in accordance with the Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health Publications No. 85–23, revised 1996).
Exercise training
Exercise training was performed as aerobic interval train-
ing for 6 weeks, 5 days/week, on an inclined (25) tread-
mill, each session starting with a 10-min warm-up at
50–60% of maximal oxygen uptake (VO2max), whereupon
exercise then alternated between 4- and 2-min intervals at
85–90 and 50–60% of VO2max, respectively for 60 min.
VO2max was assessed during a treadmill running test to
exhaustion in a metabolic chamber. After a warm-up period
of about 10 min, treadmill band velocity was increased by
0.03 m/s for every second minute until mice were not able
to maintain the treadmill velocity (Hoydal et al. 2007;
Kemi et al. 2002). To maintain the exercise intensity
throughout the experimental period, VO2max was tested at
the beginning of each week in addition to pre- and post-
tests. This exercise protocol has previously been proven
efficient for inducing exercise and cardiovascular
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adaptations in both the clinical and experimental studies
(Tjonna et al. 2008; Hoydal et al. 2007; Kemi et al. 2002,
2005; Wisloff et al. 2001; Stolen et al. 2009).
Echocardiography
High-resolution echocardiography (Vevo 770, VisualSon-
ics, Toronto, Canada) using a single-element mechanical
transducer with a center frequency of 30 MHz was per-
formed on self-breathing mice exposed to a mixture of 2%
isoflurane and 98% oxygen. A two-dimensional long-axis
view was used to visualize both ventricles, the ascending
aorta, and the right ventricular outflow tract by placing the
ultrasound transducer on the left parasternal position,
whereas a short-axis view was used to visualize systolic and
diastolic movement of both ventricles by placing the trans-
ducer horizontally above the heart. Left ventricular end-
diastolic diameter (LVEDD), left ventricular end-systolic
diameter (LVESD), interventricular septum (IVST) and
posterior wall thickness (PWT) were recorded with M-mode
echocardiography, which allowed calculation of the frac-
tional shortening (% = [(LVEDD - LVESD)/LVEDD] 9
[100]) as an index of systolic left ventricular function.
The following equation was used to calculate LV
mass (mg) = [(LVEDD ? IVST ? PWT)3 - LVEDD3] 9
1.055, where 1.055 (mg/mm3) is the density of myocardium.
IVST and PWT were measured at end diastole.
Cardiomyocyte isolation, contractile function, Ca2?
measurements and cell size
Left ventricular cardiomyocytes were isolated as previ-
ously described using a Hepes-based solution (Mitra and
Morad 1981; Guatimosim et al. 2001). Exercised hearts
were excised 24 h after the last exercise session. A mixture
of 3–4% isoflurane and 96–97% oxygen were used to
anesthetize the mice, whereupon the heart was heparinized
and removed. Until it was connected to the aortic cannula
on a standard Langendorff retrograde perfusion system, the
hearts were kept on ice cold Hepes solution. The hearts
were cleaned with a Hepes solution containing EGTA
(Sigma-Aldrich Corp., Missouri, USA) before the perfu-
sion was switched to Hepes solution with collagenase
(Worthington, Lakewood, USA), and perfusion was con-
tinued for approximately 10 min (3.5 ml/min). After the
hearts were taken down, left ventricles were carefully cut
off and gently shaken for 2 min before the non-digested
tissue was filtered out (nylon mesh, 250 lm). Further, cells
were stepwise exposed to increasing Ca2? levels (initially
0.05 mM). The isolated cells were centrifuged (30 s,
600 rpm) before solution was switched to 1.2 mM Hepes-
based solution. Fura-2/AM-loaded (2 lmol/l, Molecular
Probes, Eugene, OR, USA) cardiomyocytes were field
stimulated by bipolar electrical pulse at 1 Hz, on an
inverted epifluorescence microscope (Nikon TE-2000E,
Tokyo, Japan), whereupon cell shortening was recorded by
video-based myocyte sarcomere spacing (SarcLenTM,
IonOptix, Milton, MA, USA) and intracellular Ca2? con-
centration was measured by fluorescence after excitation
by alternating 340 and 380 nm wavelengths (F340/380 ratio)
(Optoscan, Cairn Research, Kent, UK). Cells with a clear
visual intracellular structure that were able to follow
stimulation frequency were included for the experiment.
The total number of cardiomyocytes included for all
analysis in the different groups was: sham sedentary 8,
sham exercise 20, KN-93 sedentary 5, and in KN-93
exercise 9. During the stimulation protocol, cells were kept
in 1.2 mM Ca2? HEPES-based solution at 37C. Cell size
was measured with Nikon Eclipse E400 Microscope with a
DSFil camera (Nikon NIS-Elements Basic Research Ver-
sion 3.00 software, Nikon Instruments Inc., Melville, NY,
USA). Cardiomyocyte size was measured on 80–120
cardiomyocytes per group.
Statistics
A one-way ANOVA with LSD post hoc test was used to
detect significant differences between groups. For within-
group differences from pre- to post-test, a paired sample
T test was used. Statistical significance level was set to
p \ 0.05.
Results
VO2max and exercise capacity
In sedentary mice, daily intraperitoneal injections of the
CaMKII-selective inhibitor KN-93 did not affect VO2max,
running speed at VO2max, or body mass (Fig. 1). However,
while chronic CaMKII inhibition had no effect in sedentary
mice, it did affect the response to exercise training. Whereas
exercise training increased VO2max by 8% (p \ 0.05) in
sham, the effect was 22% (p \ 0.01) in KN-93 mice after
the exercise training period (magnitude of response differ-
ence p \ 0.01, Fig. 1a). KN-93 tended to suppress the
growth in body mass (Fig. 1c), which made it necessary to
normalize VO2max according to correct scaling procedures,
which involves the correct normalization of a physiological
variable (here VO2max) to a body dimension (here body
mass). It is well established that cardiorespiratory capacity
in lighter individuals will be overestimated compared to
heavier ones when VO2max is expressed in direct relation to
body mass (i.e., ml/kg/min) and that VO2max should be
expressed with body mass raised to the power of 0.75 (i.e.,
ml/kg0.75/min) when comparing individuals that differ in
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body mass (Taylor et al. 1981). Hence, VO2max was divided
by body mass raised to the power of 0.75 as an exponent in
the present study in order not to overestimate the effect of
KN-93 on VO2max. In line with a larger increase in VO2max
after exercise training in KN-93 mice, we observed that
running speed at VO2max also increased twice as much
compared to that observed in sham mice 32% (p \ 0.01),
and 61% (p \ 0.01) in KN-93 mice.
Cardiac remodeling
KN-93 injections did not significantly change LVEDD,
LVESD, PWT, or IVST (Table 1). However, there was a
trend for decreased LV mass, and LVEDD in sedentary
KN-93 treated mice compared to sham sedentary.
Also, CaMKII inhibition by KN-93 injections did not
affect cardiomyocyte size in sedentary mice, measured as
cell length and width in isolated cardiomyocytes, but it did
blunt the exercise training-induced hypertrophy of the
cardiomyocytes. Exercise-induced cardiomyocyte hyper-
trophy was observed in both sham and KN-93 mice, but the
effect was larger in sham mice. Exercise training increased
cardiomyocyte length and width by 13% (p \ 0.05) and
30% (p \ 0.05) in sham mice, and by 8% (p \ 0.05) and
14% (p \ 0.05) in KN-93 mice, respectively (group dif-
ferences p \ 0.05, Fig. 2a, b). Thus, the cardiomyocyte
hypertrophy response to exercise in KN-93 mice was
approximately half of that in sham mice.
Fig. 1 Values of VO2max (a),
maximal aerobic running speed
(b), and body mass (c), before
and after the exercise training
intervention (pre- and post-
tests), presented as mean
values ± SD. *p \ 0.05 versus
sedentary; **p \ 0.01 versus
sedentary; ##p \ 0.01 versus
sham exercise; §p \ 0.05 versus
pre-test
Table 1 Two-dimensional echocardiography measurements
Sham KN-93
Sedentary Exercise Sedentary Exercise
n 6 4 4 4
Echocardiography
HR
(beats/min)
441 ± 21.3 450 ± 36.2 478 ± 18.0 447 ± 36.4
SV
(ll/min)
23.7 ± 4.0 25.2 ± 1.4 20.2 ± 5.7 25.4 ± 6.0
CO
(ml/min)
10.4 ± 1.8 11.3 ± 1.4 9.7 ± 2.7 11.3 ± 2.3
LVEDD
(mm)
3.7 ± 0.2 3.7 ± 0.2 3.5 ± 0.3 3.8 ± 0.2
LVESD
(mm)
2.8 ± 0.3 2.5 ± 0.3 2.6 ± 0.2 2.7 ± 0.1
LV mass
(mg)
96 ± 11.7 94 ± 8.7 85 ± 23.5 99 ± 23.0
FS (%) 25 ± 4.5 32 ± 5.2* 28 ± 3.2 30 ± 1.6
PWT
(mm)
0.69 ± 0.07 0.7 ± 0.09 0.75 ± 0.09 0.7 ± 0.11
IVST
(mm)
0.74 ± 0.06 0.66 ± 0.14 0.7 ± 0.12 0.68 ± 0.06
Data are presented as mean values ± SD
HR heart rate, SV stroke volume, CO cardiac output, LVEDD left ven-
tricular end-diastolic dimension, LVESD left ventricular end-systolic
dimension, FS fractional shortening, PWT posterior wall thickness, IVST
intraventricular septal thickness
* p \ 0.05 versus sedentary
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Cardiac contractile function
According to the measurements of in vivo cardiac function
with echocardiography, KN-93 injections did not signifi-
cantly affect heart rate, stroke volume (SV), cardiac output
or fractional shortening (Table 1; Fig. 3). In contrast to
VO2max and exercise capacity, left ventricular fractional
shortening improved from 25 to 32% after exercise training
in sham mice (28% training response, p \ 0.02). Cardiac
contractile function is largely dependent on Ca2? handling
properties. Systolic Ca2? and diastolic Ca2? level were
significantly increased by KN-93 injections (Fig. 4a, b,
p \ 0.01). Only sham exercise increased systolic Ca2?
levels (Fig. 4a, p \ 0.05), and decreased diastolic Ca2?
level (Fig. 4b, p \ 0.01).
Chronic CaMKII inhibition by KN-93 injections
induced a reduction of the cardiomyocyte ability to re-
lengthen (25% increased time to 50% re-lengthening;
Fig. 4c, p \ 0.05) after twitch contractions. This was at
least partly explained by the 16% increase in the Ca2?
transient decay time (Fig. 4d, p \ 0.05). Exercise training
normalized cardiomyocyte re-lengthening and Ca2? tran-
sient decay times to levels comparable to sedentary sham
mice, and the response to exercise training was not dif-
ferent between sham and KN-93 mice. In particular,
exercise training decreased the re-lengthening time by 12%
(p \ 0.05) and 16% (p \ 0.05) in sham and KN-93 mice,
respectively, which was linked to comparable exercise
training-induced changes in the Ca2? transient decay times
(Fig. 4c, d).
In contrast to the above, the observed effects of KN-93
and exercise training on cardiomyocyte fractional short-
ening (amplitude of the contraction) and the associated
Ca2? transient amplitude showed a more complex nature.
First, KN-93 reduced the Ca2? transient amplitude by 20%
(Fig. 4e, p \ 0.05), but this did not translate into a com-
parable reduction in the fractional shortening, as no effect
was observed. Second, fractional shortening improved by
exercise training, but the response was blunted in KN-93
mice compared to sham mice. Exercise training in sham
mice increased fractional shortening by 63% (p \ 0.01),
but only by 18% (p \ 0.05) in KN-93 mice (magnitude of
response difference p \ 0.05, Fig. 4f). This could not be
solely explained by changes to the Ca2? transient ampli-
tude, as the exercise training response did not differ
between sham and KN-93 mice; sham increased by 64%
(p \ 0.01), and KN-93 by 47% (p \ 0.01) in response to
exercise training (Fig. 4e). Table 2 provides an overview
of the effects of CaMKII inhibition on whole-body and
cardiac, and cardiomyocyte exercise training response.
Discussion
Given that (1) experimental trials (Anderson 2005; Zhang
et al. 2005; Grimm and Brown 2010) have raised the
possibility that systemic CaMKII inhibition may be a via-
ble and effective strategy for the treatment of heart disease,
and (2) exercise training in both experimental (Rose et al.
2007; Wisloff et al. 2002; Stolen et al. 2009) and clinical
Fig. 2 Isolated cardiomyocyte dimension; cell length (a), and cell width (b), presented as mean values ± SD. *p \ 0.05 versus sedentary;
#p \ 0.05 versus KN-93 exercise
Fig. 3 In vivo LV fractional shortening, presented as mean val-
ues ± SD. *p \ 0.05 versus sedentary
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(Adams et al. 2005; Erbs et al. 2010; Hambrecht et al.
2000; Mezzani et al. 2008; Wisloff et al. 2007) trials show
improved heart function in similar scenarios of heart dis-
ease, we aimed to test the potential value of combining
those strategies; first in normal healthy mice. The reasoning
for the latter is that exercise training and CaMKII also
interact in the heart, as the inotropic effects of exercise
training are at least partly modulated by an exercise
training-induced increase in CaMKII activity (Kemi et al.
2007). This complicates the combination scenario as
CaMKII seems to act as a two edged sword. In fact,
CaMKII contributes to decompensate pathologic hyper-
trophy to heart failure, mainly by its action on the RyR2 to
increase SR Ca2? leak (Sag et al. 2009; Ling et al. 2009).
Thus, the possibility arises that chronic CaMKII inhibition
and exercise training may oppose each other, though it
remains to be studied.
As such, this is the first study to introduce the combi-
nation of chronic CaMKII inhibition by daily KN-93
injections and aerobic interval exercise training. The main
finding was that chronic CaMKII inhibition blunted several
Fig. 4 Cardiomyocyte systolic
Ca2? level (a), diastolic Ca2?
level (b), time to 50% diastolic
re-lengthening (c), Ca2?
transient decay time (d),
intracellular Ca2? transient
amplitude (e), and fractional
shortening (f), presented as
mean values ± SD. *p \ 0.05
versus sedentary; **p \ 0.01
versus sedentary; #p \ 0.05
versus KN-93 exercise;
##p \ 0.01 versus KN-93
exercise; §p \ 0.05 versus sham
sedentary; §§p \ 0.01 versus
sham sedentary
Table 2 Comparison of effects of CaMKII inhibition on exercise
training response
Variable Sham
exercise
KN-93
exercise
Aerobic exercise capacity
VO2max : ::
Echocardiography
LV fractional shortening : $
Cardiomyocyte Ca2? handling
Systolic Ca2? : :
Diastolic Ca2? ; $
Fractional shortening :: :
Ca2? transient amplitude : :
Time to 50% re-lengthening ; ;
Time to 50% Ca2? decay ; ;
Cardiomyocyte dimension
Cell length :: :
Cell width :: :
:, indicates value increase; ;, value decrease; $, value remain
unchanged; 1 or 2 arrows, indicate size of exercise-induced response
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aspects of the response patterns of cardiomyocyte contrac-
tility, and intracellular Ca2? handling to exercise training,
but it did not fully prevent such adaptations. Moreover,
CaMKII inhibition also enhanced exercise training-induced
improvements on VO2max and aerobic exercise capacity,
whereas it did not affect either of them in sedentary mice.
Mechanisms of exercise training-induced adaptation
The present study provides several mechanistic clues as to
the response to exercise training. First, it shows that while
CaMKII activation contributes to the cardiac improve-
ments after exercise training (Kemi et al. 2007), other
mechanisms must also contribute, as CaMKII inhibition
only partly blunted the exercise response. Whether those
mechanisms naturally co-exist or occur to compensate for
the loss of CaMKII activation remains unknown.
Second, the finding that VO2max and exercise capacity
responded more to exercise training in the presence of the
chronic CaMKII inhibition compared to the absence
thereof indicates that CaMKII also may negatively regulate
exercise adaptation in peripheral organs. While this
requires further investigation, it is plausible all the while it
is ubiquitous and exists in most, if not all, cellular systems
(Hudmon and Schulman 2002; Chin 2004).
Third, the opposite effects of exercise training on VO2max
and exercise capacity on the one side, and cardiac inotropy
and hypertrophy on the other side in the face of CaMKII
inhibition highlights that other organs are important in
determining VO2max (Bassett and Howley 2000; Coffey and
Hawley 2007). In particular, chronic exercise training
elicits resistance to muscle fatigue through metabolic
responses including mitochondrial biogenesis, increased
oxidative capacity, and alterations in gene and protein
expression that ultimately leads to phenotype changes that
support endurance-type activity (Rose et al. 2007; Benziane
et al. 2008; Chin 2004; Coffey and Hawley 2007; Bassett
and Howley 2000). The exact mechanism of this rather
surprising observation is not known; however, the interac-
tion between CaMKII and calcineurin is a possible candi-
date. CaMKII modulation of calcineurin signaling is
released by CaMKII inhibition. Calcineruin modulates
exercise-induced skeletal muscle phenotypes and enhances
exercise capacity through increase in mitochondrial oxida-
tive function and energy substrate storage in skeletal mus-
cles (Wang et al. 2011; Jiang et al. 2010). This should be
elucidated in future studies.
Cardiac contractile capacity, Ca2? handling,
and CaMKII
Both in vivo and cellular fractional shortening were unaf-
fected by KN-93-induced inhibition of CaMKII in
sedentary mice, whereas the expected training-induced
increase in both whole-heart and cellular fractional short-
ening was blunted by the chronic KN-93 treatment. How-
ever, chronic CaMKII inhibition did reduce the rate of
diastolic cellular relaxation in sedentary mice, which was
explained by slower intracellular Ca2? removal (longer
time to 50% Ca2? transient decay) and higher systolic
Ca2? levels. Exercise training normalized Ca2? removal
times, and in contrast to fractional shortening, the effect
was not blunted by CaMKII inhibition. These results are in
accordance with Kemi et al. (2007), who found that acute
pre-incubation, with AIP (comparable CaMKII inhibitor)
in isolated cardiomyocytes also blunted the exercise
training-induced improvements in cellular contractility.
Together, these results suggest that CaMKII at least partly
modulates the exercise training-induced improvements in
cardiac contractility, excitation–contraction coupling, and
intracellular Ca2? handling (Kemi et al. 2007; Stolen et al.
2009). The accumulated evidence also suggests that this
modulation occurs via targeting of several loci of excita-
tion–contraction coupling and Ca2? handling (Stolen et al.
2009). Indeed, fractional shortening is dependent on both
SR Ca2? release and myofilaments Ca2? sensitivity, where
the latter may explain the dissociation between fractional
shortening and the intracellular Ca2? transient amplitude in
the present study, as shown directly by others after exercise
training (de Waard et al. 2007; Diffee et al. 2001). How-
ever, in our experiments we used unloaded myocytes where
tension development and basal sarcomere length were not
considered.
Current results together with the previous studies
(Anderson 2005; Anderson et al. 1998; Couchonnal and
Anderson 2008; Erickson and Anderson 2008; Kemi et al.
2007; Khoo et al. 2006; Maier and Bers 2002; Maier et al.
2007; Sag et al. 2009; Vila-Petroff et al. 2007; Zhang
et al. 2005) suggest that CaMKII is a versatile kinase that
may shift cardiac function into different and also opposite
phenotypes. In healthy mice, it appears that a controlled
increase in the CaMKII activity increases cardiac con-
traction (Kemi et al. 2007); that CaMKII inhibition reduces
cardiac contraction, and that these effects mainly occur
because CaMKII inhibition reduces SR Ca2? uptake via
SERCA2a. Therefore, it is also possible that the depression
of cardiomyocyte contractile parameters by chronic
CaMKII inhibition observed here might have progressed to
a global dysfunction and a failure if CaMKII inhibition was
continued. As such, maintained CaMKII seems to be
important for normal cardiomyocyte function in healthy
mice. In contrast, the cardiac dysfunction that also has been
linked to increased CaMKII activity (Ai et al. 2005;
Couchonnal and Anderson 2008; Maier et al. 2007; Zhang
and Brown 2004) has mainly been attributed to hypersen-
sitization of the RyR2 to luminal Ca2? with subsequent
Eur J Appl Physiol (2012) 112:579–588 585
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diastolic SR Ca2? leak and a shift of Ca2? out of the cell; a
scenario that may lead to contractile dysfunction and
increased propensity for arrhythmic events (Sag et al. 2009;
Ai et al. 2005; Grimm and Brown 2010; Khoo et al. 2006;
Ling et al. 2009; Stolen et al. 2009; Wu et al. 2002), in
which CaMKII inhibition or reduction would become
particularly beneficial (Kemi et al. 2007; Laurita and
Rosenbaum 2008; Li et al. 2006; Vila-Petroff et al. 2007;
Yang et al. 2006; Zhang et al. 2005). In a recent modula-
tion study, Hashambhoy et al. (2010) report that inhibition
of CaMKII phosphorylation of the L-type Ca2? channel
rather than the RyR2 is more effective in modulating dia-
stolic RyR2 flux. Thus, a pharmacological approach of
CaMKII inhibition in the heart should also target the
L-type Ca2? channel in order to prevent or treat cardiac
dysfunction and disease. Whether this will be feasible
remains to be investigated. KN-93 inhibits CaMKII by
competing for the calmodulin binding site, and has been
widely used to implicate roles of CaMKII in Ca2? handling
(Sumi et al. 1991). KN-93 is not heart-specific and is
known to have other actions than CaMKII inhibition
(Anderson et al. 1998; Gao et al. 2006). Previous studies
have observed that KN-93 might inhibit L-type Ca2? cur-
rent independent of CaMKII (Anderson et al. 1998; Gao
et al. 2006). This negative effect of KN-93 on intracellular
Ca2? levels are balanced by inhibition of voltage-depen-
dent potassium currents which enhance Ca2? entry via
L-type Ca2? channel (Anderson et al. 1998; Rezazadeh
et al. 2006; Ledoux et al. 1999). The lack of organ speci-
ficity of KN-93 is a limitation of this study, and interpre-
tations should be considered with caution. We did,
however, control for non-cardiac side effects of chronic
KN-93 injections by the pathological examinations of the
vital organs after euthanasia in mice.
Physiological hypertrophy
Echocardiography measurements observed a trend for
decreased LV mass in sedentary KN-93 treated mice,
which was normalized by exercise-induced hypertrophy,
and cardiomyocyte length and width increased significantly
less in KN-93-treated mice compared to sham-treated mice.
These results are somewhat similar to the observations of
Zhang et al. (2005), with myocardial infarction as the
physiological stressor, who reported that cardiomyocyte
transverse cross-sectional area and heart weight were
comparably smaller after genetic inhibition of CaMKII
than in control cardiomyocytes. Furthermore, Ramirez
et al. (1997) reported that pre-treatment with KN-93
blocked hypertrophic responses to the hypertrophy devel-
oped by pressure overload or endothelin-1 (Zhang et al.
2004; Zhu et al. 2000). Our observation suggests that
CaMKII may also modulate cardiomyocyte growth in
response to exercise training (physiological hypertrophy)
and not only in response to the pathologic conditions.
Conclusion
This study indicates the importance of maintaining normal
CaMKII activity in cardiomyocytes of healthy individuals,
also because it positively modulates inotropic/lusitropic
responses to exercise training. However, targeting CaMKII
by selective inhibitors has recently been suggested to cor-
rect cardiac dysfunction and prevent decompensation and
progression of heart disease; a clinical scenario that also is
targeted by exercise training. This study indicates that a
combination strategy of CaMKII inhibition and exercise
training may be feasible for the purpose of attenuating
heart disease, although this does present a complex sce-
nario that may also reduce some of the beneficial effects of
exercise training, especially if CaMKII inhibitors cannot be
closely tuned into localized subcellular targets that mainly
cause the cardiac dysfunction.
Limitations
The small molecule inhibitor KN-93 has potential non-
specific effects other than CaMKII inhibition which were
not controlled for; this is a limitation of the present study.
The pathological examinations were done to rule out
effects on the results from any of the other vital organs due
to KN-93 or DMSO injections.
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